Foxwynd Foundation Awards $75,000 Grant to Our Rescue to support Riverside County ICAC Efforts to Combat Child Exploitation

Our Rescue, a global nonprofit organization has been awarded a $75,000 grant from the Foxwynd Foundation to advance its mission to end Sex Trafficking and Child Exploitation, by supporting the Riverside County Internet Crimes Against Children (ICAC) Task Force. This grant will support Our Rescue's regional operational program – strengthening the capacity of the Riverside […]

Halper Sadeh LLC Encourages CFLT, SNCR, WBD Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: https://mma.prnewswire.com/media/1896150/Firm_Logo_with_Investor_Law_Firm_Logo.jpg Confluent, Inc. (NASDAQ: CFLT)'ssale to IBM for $31.00

LandQuire and No Limits Announce Strategic Partnership to Unlock High-Yield Real Estate Investment Opportunities

Hollywood, FL, Dec. 08, 2025 (GLOBE NEWSWIRE) — No Limits and LandQuire Form a Strategic Partnership to Offer Entrepreneurs High-Yield Real Estate Investment Opportunities in Europe and the United States Strategic Partnership: No Limits and LandQuire Real Estate Investment in US Land for European Entrepreneurs Geneva, Switzerland, November 20, 2025 No Limits, the all-in-one application

LandQuire and No Limits Announce Strategic Partnership to Unlock High-Yield Real Estate Investment Opportunities

LandQuire and No Limits Announce Strategic Partnership to Unlock High-Yield Real Estate Investment Opportunities Collaboration aims to connect European entrepreneurship with the potential of the U.S. real estate market. GlobeNewswire December 08, 2025 Hollywood, FL, Dec. 08, 2025 (GLOBE NEWSWIRE) — No Limits and LandQuire Form a Strategic Partnership to Offer Entrepreneurs High-Yield Real Estate

BioMatrix Infusion Pharmacy Expands Western U.S. Footprint with Acquisition of Total Infusion Care

BioMatrix Infusion Pharmacy, a national leader in home and ambulatory infusion services, today announced the acquisition of Total Infusion Care (TIC), a Nevada-based infusion therapy provider serving patients across the western United States. The transaction closed on November 7, 2025. https://mma.prnewswire.com/media/2406871/BioMatrix_Specialty_Infusion_Pharmacy_Logov1.jpg Founded in 2012, Total Infusion Care has established itself as a market-leading infusion services

AI Chip Market worth $564.87 billion by 2032 – Exclusive Report by MarketsandMarkets™

According to MarketsandMarkets™, the AI Chip Market is projected to grow from USD 203.24 billion in 2025 to USD 564.87 billion by 2032; it is expected to grow at a compound annual growth rate (CAGR) of 15.7% from 2025 to 2032. https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg Browse 120 market data Tables and 40 Figures spread through 360 Pages and

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

(NASDAQ:CGEM), CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting GlobeNewswire December 08, 2025 CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed

Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition

— Two oral presentations will highlight Phase 2 results from the ASTX030-01 trial of oral azacitidine and cedazuridine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia or acute myeloid leukemia and Phase 2 results from ASTX727-03 trial of low-dose oral decitabine and cedazuridine in patients with lower-risk myelodysplastic syndromes — New data from 15 company-sponsored

ASTHO Announces Top Five Public Health Legislative Priorities for 2026

The Association of State and Territorial Health Officials (ASTHO) released its top five state public health policy issues for 2026, which provide expert analysis on legislative priorities that will shape public health in the coming year. ASTHO's annual Legislative Prospectus Series provides concise, evidence-based policy guidance for public health leaders, lawmakers, and other decision makers

Scroll to Top